Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables - Other: 2015-2024

Historic Receivables - Other for Zevra Therapeutics (ZVRA) over the last 2 years, with Dec 2024 value amounting to $333,000.

  • Zevra Therapeutics' Receivables - Other fell 73.53% to $333,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $333,000, marking a year-over-year decrease of 73.53%. This contributed to the annual value of $333,000 for FY2024, which is 73.53% down from last year.
  • Per Zevra Therapeutics' latest filing, its Receivables - Other stood at $333,000 for Q4 2024, which was down 73.53% from $1.3 million recorded in Q4 2023.
  • In the past 5 years, Zevra Therapeutics' Receivables - Other ranged from a high of $1.3 million in Q4 2023 and a low of $107,000 during Q4 2021.
  • In the last 3 years, Zevra Therapeutics' Receivables - Other had a median value of $550,000 in 2022 and averaged $684,167.
  • Per our database at Business Quant, Zevra Therapeutics' Receivables - Other spiked by 941.12% in 2022 and then tumbled by 73.53% in 2024.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Receivables - Other stood at $137,000 in 2020, then declined by 21.90% to $107,000 in 2021, then spiked by 941.12% to $1.1 million in 2022, then grew by 12.93% to $1.3 million in 2023, then crashed by 73.53% to $333,000 in 2024.
  • Its last three reported values are $333,000 in Q4 2024, $1.3 million for Q4 2023, and $700,000 during Q1 2023.